Narcolepsy and Cataplexy in Children
Overview
Narcolepsy is a chronic neurological sleep disorder characterized by excessive daytime sleepiness (EDS) and, in many cases, cataplexy—a sudden loss of bilateral muscle tone triggered by emotions. 1
Core Clinical Features
Primary Symptoms (The Pentad)
- Excessive daytime sleepiness (EDS): Present in nearly all pediatric cases (32 of 33 children at presentation), representing the most consistent and debilitating symptom 2
- Cataplexy: Reported in approximately 85% of pediatric narcolepsy cases (28 of 33 children) at presentation 2
- Sleep paralysis: Brief inability to move or speak when falling asleep or waking up 1
- Hypnagogic/hypnopompic hallucinations: Vivid, often frightening dream-like experiences occurring at sleep onset or upon awakening 1
- Disrupted nighttime sleep: Fragmented sleep with frequent awakenings 3
Unique Pediatric Presentations of Cataplexy
Cataplectic Facies (Pediatric-Specific Presentation)
Children, particularly younger and obese children, often present with "cataplectic facies"—a previously unrecognized form of cataplexy consisting of semipermanent facial hypotonia and/or tongue protrusion, which should raise immediate suspicion for narcolepsy. 2, 4
Cataplectic facies was reported in 64% (18 of 28) of children with cataplexy, characterized by:
Children with cataplectic facies tend to be:
Classic Cataplexy Features in Children
- Most commonly affected body segments during attacks: knees, head, and jaw (in descending order), with eyelids, arms, and trunk less commonly involved 4
- Falls occur in 43% of pediatric cataplexy episodes 4
- Associated symptoms may include blurred vision, slurred speech, irregular breathing, or sudden loss of smiling mimics 4
- Triggering emotions (laughter, joking, anger) are not always present, especially near disease onset, which can delay diagnosis 4
Natural Evolution of Pediatric Narcolepsy
Disease Progression Over Time
At onset, childhood narcolepsy is characterized by an abrupt increase in total 24-hour sleep time, generalized hypotonia, and motor overactivity; over 3 years, cataplexy evolves into the classic adult presentation while total sleep time normalizes to age-appropriate levels. 5
At diagnosis (mean age 10 years, disease duration 1 year):
At follow-up (median 3 years from symptom onset):
Associated Features and Comorbidities
Common Accompanying Symptoms
- Sleep inertia during awakening (difficulty transitioning to full wakefulness) 6
- REM behavior symptoms (acting out dreams) 6
- Behavioral problems and serious school difficulties 6
- Emotional problems affecting social interaction and quality of life 1
Cardiovascular Dysregulation
Children with narcolepsy with cataplexy demonstrate downregulated blood pressure profiles with higher heart rates and reduced diurnal variation (non-dipping pattern), reflecting hypothalamic dysregulation beyond sleep-wake control. 7
- Pre-treatment findings: Lower diurnal systolic blood pressure (-6.5 mmHg) but higher heart rate (+11.0 bpm) compared to matched controls, particularly during wake time 7
- Diastolic blood pressure remains comparable to controls 7
Diagnostic Considerations
Clinical Red Flags
A child presenting with excessive daytime sleepiness combined with facial hypotonia or tongue protrusion—especially if young and obese—warrants immediate referral to a specialized sleep facility. 2
- Mean age at first symptoms: 14.0 ± 3.0 years 6
- Mean age at diagnosis: 15.6 ± 3.1 years (indicating significant diagnostic delay) 6
- Disease duration before diagnosis: Approximately 1 year 5
Polysomnographic Features
- Multiple Sleep Latency Test (MSLT): Mean sleep latency of 4.0 ± 3.1 minutes with 3.2 ± 1.4 sleep-onset REM periods (SOREMs) 6
- Nocturnal polysomnography in narcolepsy with cataplexy shows higher wakefulness and superficial NREM stage 1 sleep, with lower NREM stage 3 sleep 6
- Epworth Sleepiness Scale: High scores (17.1 ± 2.5) indicate severe excessive daytime sleepiness 6
Predictive Limitations
Clinical and polysomnographic parameters at initial presentation cannot reliably predict whether children with narcolepsy without cataplexy will develop cataplexy later in life. 6
- No significant differences in MSLT findings, HLA-DQB1*0602 typing, or most clinical features between narcolepsy with and without cataplexy groups 6
- Narcolepsy without cataplexy is diagnosed in approximately 40% of pediatric cases 6
Pathophysiology
Hypocretin/Orexin Deficiency
Pediatric narcolepsy with cataplexy is caused by loss of hypothalamic hypocretin/orexin neurons, confirmed by hypocretin-1 deficiency in cerebrospinal fluid testing. 5
- Hypocretin-1 deficiency was confirmed in 19 of 21 children with narcolepsy with cataplexy in longitudinal studies 5
- The hypocretin system connects to both brain alertness systems and brainstem nuclei regulating cardiovascular function 7
Thermoregulatory Mechanisms
Recent evidence demonstrates that cataplexy and REM sleep are dissociated by skin thermal dynamics and hypothalamic melanin-concentrating hormone (MCH) neuron thermosensitivity, with skin cooling promoting cataplexy and skin warming favoring REM sleep. 8
- Reduced skin temperatures and widening distal-to-proximal skin temperature gradient precede cataplexy episodes 8
- MCH neuron activity increases during both cataplexy and REM sleep, but skin cooling reduces MCH dynamics associated with cataplexy 8
Treatment Approach
Pharmacological Management
The American Academy of Sleep Medicine conditionally recommends both modafinil and sodium oxybate for treating pediatric narcolepsy, with sodium oxybate showing moderate-quality evidence for improving cataplexy, disease severity, and excessive daytime sleepiness. 9
Modafinil
- Indication: Treatment of excessive daytime sleepiness in pediatric narcolepsy 9
- Evidence quality: Very low (one observational study showing clinically significant improvement in EDS) 9
- FDA status: Not approved for patients <17 years; carries black box warning for Stevens-Johnson syndrome and psychosis based on pediatric case reports 9
- Schedule: FDA Schedule IV controlled substance 9
- Common adverse events: Irritability, dry mouth, nausea, headaches 9
- Serious adverse events: No SJS or psychosis reported in the reviewed study 9
- Contraceptive interaction: May reduce effectiveness of oral contraception 9
Sodium Oxybate
- Indication: Treatment of narcolepsy in pediatric patients (addresses EDS, cataplexy, and disease severity) 9
- Evidence quality: Moderate (one prospective double-blind, placebo-controlled, randomized-withdrawal study plus three observational studies) 9
- FDA status: Carries black box warning for CNS depression and respiratory depression; Schedule III controlled substance (sodium salt of GHB, a Schedule I substance) 9
- Distribution: Only available through REMS programs using certified pharmacies 9
- Common adverse events: Weight loss, enuresis, nausea, vomiting, headache, decreased appetite, nasopharyngitis, dizziness 9
- Serious adverse events: Central sleep apnea, depression, suicidality 9
- Abuse risk: Illicit GHB abuse associated with seizures, respiratory depression, decreased consciousness, coma, and death, especially with other CNS depressants 9
Methylphenidate Effects
- Cardiovascular impact: Methylphenidate (18 mg sustained release) increases waketime systolic blood pressure (+4.6 mmHg), diastolic blood pressure (+3.3 mmHg), and heart rate (+7.1 bpm) in children with narcolepsy with cataplexy 7
- Nighttime values: Remain unchanged from pre-treatment baseline 7
- Note: The AASM guideline review did not identify eligible studies for methylphenidate, amphetamines, scheduled naps, or SSRI/SNRI medications for pediatric narcolepsy 9
Comprehensive Management
Treatment should combine pharmacological interventions with behavioral modifications and psychosocial support involving close cooperation between the child, school, family, and medical personnel. 1
- Behavioral modifications: Sleep hygiene, scheduled naps, activity planning 1
- Educational support: School accommodations for excessive sleepiness and cognitive difficulties 1
- Mental health support: Address emotional and behavioral problems that commonly accompany the disorder 1
Clinical Pitfalls to Avoid
Diagnostic Delays
- Do not dismiss facial hypotonia or tongue protrusion as benign findings in children with excessive daytime sleepiness 2
- Do not wait for classic cataplexy triggers (laughter, joking) to be present, as they may be absent near disease onset 4
- Do not assume narcolepsy without cataplexy will remain stable; however, recognize that predicting cataplexy development is not currently possible 6
Treatment Considerations
- Do not overlook the black box warnings for both modafinil (SJS, psychosis) and sodium oxybate (CNS depression, respiratory depression) 9
- Do not prescribe sodium oxybate without enrolling patients in REMS programs 9
- Do not ignore cardiovascular monitoring in children treated with stimulants, given the baseline cardiovascular dysregulation in narcolepsy 7
- Do not focus solely on excessive daytime sleepiness and cataplexy; address the full spectrum of symptoms including nighttime sleep disruption, cognitive difficulties, and psychosocial impairment 3